- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Reimbursement, US reimbursement, Journal, Medicaid: Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022. (Pubmed Central) - Nov 16, 2024
These pharmacokinetic and safety findings support BUP-XR injection into the upper arm, thigh, and buttocks. The number of extended release buprenorphine injection prescriptions among US Medicaid beneficiaries treated for opioid use disorder increased from over 4000 prescriptions in 2018 to over 185?000 in 2022 but uptake is much less than observed in other countries over shorter time periods.
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Journal: Buprenorphine: two adolescent case reports of bridging the transmucosal form to the extended-release subcutaneous injectable form. (Pubmed Central) - Oct 30, 2024
A recent study analyzed buprenorphine and naltrexone treatment amongst OUD in adolescents between 2001-2014; only 1 in 4 youth received any medication therapy within six months of diagnosis...The following case report aims to demonstrate how subcutaneous extended release buprenorphine treatment can be initiated effectively as an outpatient in an adolescent with OUD. It is critical that clinicians work to expand access to pharmacotherapy for adolescents struggling with OUD to ensure proper management and reduction of opioid-related overdoses.
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Enrollment open: INDV-6001 Multiple-Dose Pharmacokinetic Study (clinicaltrials.gov) - Oct 8, 2024
P2, N=122, Recruiting,
It is critical that clinicians work to expand access to pharmacotherapy for adolescents struggling with OUD to ensure proper management and reduction of opioid-related overdoses. Not yet recruiting --> Recruiting
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Enrollment change, Trial completion date, Trial primary completion date: Evaluating the SUBLOCADE Treatment Exit Strategy (clinicaltrials.gov) - Oct 2, 2024
P=N/A, N=25, Recruiting,
Not yet recruiting --> Recruiting N=50 --> 25 | Trial completion date: Sep 2024 --> May 2025 | Trial primary completion date: Sep 2024 --> May 2025
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Trial completion date, Trial primary completion date: BOPAT: Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections (clinicaltrials.gov) - Sep 25, 2024
P2, N=90, Recruiting,
More rapid uptake in rural areas is reassuring and suggests that this form of OAT may be supporting treatment access to those with barriers to more traditional treatment formulations. Trial completion date: Dec 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> May 2025
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Trial completion date, Trial primary completion date: Assessing Optimal XRB Initiation Points in Jail (clinicaltrials.gov) - Sep 19, 2024
P4, N=200, Not yet recruiting,
Trial completion date: Dec 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> May 2025 Trial completion date: Jun 2026 --> Oct 2026 | Trial primary completion date: Feb 2026 --> Jun 2026
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Trial completion date, Trial initiation date, Trial primary completion date: Assessing Optimal XRB Initiation Points in Jail (clinicaltrials.gov) - Jun 28, 2024
P4, N=200, Not yet recruiting,
N=489 --> 785 | Active, not recruiting --> Completed Trial completion date: Jan 2026 --> Jun 2026 | Initiation date: Mar 2024 --> Jul 2024 | Trial primary completion date: Oct 2025 --> Feb 2026
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Journal: Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended - Release Subcutaneous Injection: A Case Report. (Pubmed Central) - Jun 16, 2024
Opioid use disorder (OUD) continues to be a major public health crisis, with the current epidemic being driven by synthetic opioids such as illicitly manufactured fentanyl...This case supports the use of buprenorphine extended-release in pediatric patients who are at high risk. While buprenorphine extended-release injections are not Food and Drug Administration-approved for pediatric patients, the increase in adolescent overdose deaths and lack of access to treatment in this age group support the need for increased research and treatment options for youth with OUD.
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Enrollment change, Trial withdrawal: Assessing Optimal XR-Buprenorphine Initiation Points in Jail (clinicaltrials.gov) - Feb 29, 2024
P4, N=0, Withdrawn,
A small, but appreciable number of people switched brands, suggesting that it remains important to have treatment options available. N=200 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Trial completion date, Trial termination, Trial primary completion date: Monthly Injectable BUP for MA Use Disorder (MURB) Trial (clinicaltrials.gov) - Feb 15, 2024
P2, N=18, Terminated,
N=200 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Jun 2025 --> Nov 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Oct 2023; Side effects of medication
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Trial completion date, Trial primary completion date: Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder (clinicaltrials.gov) - Feb 15, 2024
P2, N=40, Suspended,
Trial completion date: Jun 2025 --> Nov 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Oct 2023; Side effects of medication Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Enrollment change, Trial completion date, Trial primary completion date: Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults (clinicaltrials.gov) - Feb 15, 2024
P4, N=796, Recruiting,
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 N=301 --> 796 | Trial completion date: Apr 2025 --> Dec 2024 | Trial primary completion date: Oct 2024 --> Jun 2024
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Journal: The Devil's in the Depot Details: Case of Iatrogenic Opioid Intoxication After Buprenorphine Injection Requiring Surgical Excision. (Pubmed Central) - Feb 12, 2024
In the event of adverse medication effects including oversedation, LAI-BUP can be surgically excised up to 14 days after administration (https://www.sublocadehcp.com/dosing-administration)...We report a case of a man with methamphetamine use disorder and multiple unintentional fentanyl overdoses who inadvertently received LAI-BUP for overdose protection...Providers seeking to use LAI-BUP to prevent overdose among those with unintentional opioid exposure must ensure sublingual buprenorphine tolerance before injection to avoid iatrogenic harm. Although manufacturer instructions mention that LAI-BUP can be excised under local anesthesia within 14 days of insertion, ideal excision is best performed in a setting with surgical instruments and cautery-such as the operating room-as the depot can adhere strongly to the surrounding subcutaneous tissue.
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
P3 data, Journal, HEOR, Head-to-Head, Cost-effectiveness, Cost effectiveness: Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care (Pubmed Central) - Dec 4, 2023
P3
Participants (adults aged ? 18 years; all meeting DSM-5 diagnostic criteria for moderate or severe OUD at admission to their current maintenance treatment episode) were randomly assigned (1:1) to receive continued daily SoC (liquid methadone (usual dose range: 60-120
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Trial completion: Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations (clinicaltrials.gov) - Nov 2, 2023
P4, N=88, Completed,
18 years; all meeting DSM-5 diagnostic criteria for moderate or severe OUD at admission to their current maintenance treatment episode) were randomly assigned (1:1) to receive continued daily SoC (liquid methadone (usual dose range: 60-120 Active, not recruiting --> Completed
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Enrollment closed, Enrollment change: Monthly Injectable BUP for MA Use Disorder (MURB) Trial (clinicaltrials.gov) - Oct 4, 2023
P2, N=18, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=246 --> 18
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Enrollment open: SUBLOCADE Long-term Outcomes (clinicaltrials.gov) - Sep 5, 2023
P=N/A, N=1200, Recruiting,
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Enrollment open: Evaluating the SUBLOCADE Treatment Exit Strategy (clinicaltrials.gov) - Aug 22, 2023
P=N/A, N=50, Recruiting,
No abstract available Not yet recruiting --> Recruiting
- |||||||||| Edurant (rilpivirine) / J&J, Sublocade (buprenorphine once-monthly depot) / Indivior, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New P1 trial, Adherence: CHOICE: Combined Injectable Treatment for HIV and OUD (clinicaltrials.gov) - Aug 14, 2023
P1, N=40, Recruiting,
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Trial completion date, Trial initiation date, Trial primary completion date: Assessing Optimal XR-Buprenorphine Initiation Points in Jail (clinicaltrials.gov) - Jul 20, 2023
P4, N=200, Not yet recruiting,
Recruiting --> Suspended Trial completion date: Feb 2024 --> Feb 2026 | Initiation date: May 2023 --> Nov 2023 | Trial primary completion date: May 2023 --> Nov 2025
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Trial completion date, Trial primary completion date: INDV-6000-401: Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users (clinicaltrials.gov) - May 17, 2023
P4, N=489, Recruiting,
Trial completion date: Feb 2024 --> Feb 2026 | Initiation date: May 2023 --> Nov 2023 | Trial primary completion date: May 2023 --> Nov 2025 Trial completion date: Apr 2024 --> Jul 2024 | Trial primary completion date: Apr 2023 --> Jul 2024
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
New trial: SUBLOCADE Long-term Outcomes (clinicaltrials.gov) - May 16, 2023
P=N/A, N=1200, Not yet recruiting,
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Journal: Opioid Use Disorder: Treatment Outcomes in U.S. Veterans. (Pubmed Central) - May 8, 2023
Recent studies have shown Sublocade effectively blocks the effects of other opioids and minimizes the risk of medication diversion that occurs with Suboxone. For these reasons, Sublocade is an alternative medication-assisted treatment for veterans with opioid use disorder.
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Journal: Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings. (Pubmed Central) - Mar 16, 2023
P3
For these reasons, Sublocade is an alternative medication-assisted treatment for veterans with opioid use disorder. Participants from BUP-XR clinical trials who continued into RECOVER maintained or improved on numerous outcomes over 18 months, demonstrating the long-term positive impact of OUD pharmacotherapy.
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Trial completion, Trial completion date: EXPO: Extended-release Pharmacotherapy for Opioid Use Disorder (clinicaltrials.gov) - Mar 9, 2023
P3, N=342, Completed,
Participants from BUP-XR clinical trials who continued into RECOVER maintained or improved on numerous outcomes over 18 months, demonstrating the long-term positive impact of OUD pharmacotherapy. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2023
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
An Unusual Case of Delayed Type 1 Hypersensitivity to Subcutaneous Extended-Release Buprenorphine () - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1818;
Resolution of symptoms occurred each time following intramuscular epinephrine, dexamethasone, and antihistamine administration...Initially, these episodes were thought to be secondary to meloxicam and orphenadrine, both recently prescribed for acute back pain...Subsequently, oral suboxone was held as well but the reactions persisted. Allergic reactions ceased with Sublocade discontinuation despite our patient remaining on oral Suboxone.
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Trial completion date, Trial primary completion date: Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults (clinicaltrials.gov) - Dec 15, 2022
P4, N=301, Recruiting,
Allergic reactions ceased with Sublocade discontinuation despite our patient remaining on oral Suboxone. Trial completion date: Apr 2024 --> Jan 2025 | Trial primary completion date: Apr 2024 --> Jul 2024
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Trial initiation date: Assessing Optimal XR-Buprenorphine Initiation Points in Jail (clinicaltrials.gov) - Dec 7, 2022
P4, N=180, Not yet recruiting,
Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2023 Initiation date: Nov 2022 --> Feb 2023
|
